BRIDGenomics spans diagnostic and life science market segments. We provide intelligence to support genomics based strategies and commercialization of services and products. Our Genomic expertise is built on over 20 years combined global experience in medical device manufacturing, emerging technologies and diagnostics. We bridge industry segments to enable optimization of your market strategy and development pipeline while addressing your needs for a robust regulatory development process. Right Market<>Right Technology<>Right Partner<>On Time With a decade of commercial experience in Next Generation Sequencing (NGS) and advanced sequencing technologies we provide business and technology acumen. We connect IVD companion diagnostic manufacturers, pharma trials, central laboratories and LDT specialty laboratories and help you identify the right path to partnering or outsourcing. • Consulting and Partnering • NGS, Genomics, Personalized medicine • LDT Development Process • Emerging Technology Potential
View Top Employees from BRIDGenomicsWebsite | http://www.bridgenomics.com |
Revenue | $200000 |
Employees | 6 (1 on RocketReach) |
Address | 242 PO Box, Friendsville, Tennessee 37737, US |
Technologies |
JavaScript,
HTML,
Twitter
+8 more
(view full list)
|
Industry | Biotechnology, Business Services General, Business Intelligence, Business Services, Technology Landscape, Market Evaluation, Fit and Strategic Planning, Development Process Quality Management System |
Competitors | Genei Laboratories Pvt Ltd, MOgene, Proteos |
SIC | SIC Code 87 Companies, SIC Code 873 Companies |
NAICS | NAICS Code 54 Companies, NAICS Code 54171 Companies, NAICS Code 541 Companies, NAICS Code 541713 Companies, NAICS Code 5417 Companies |
Looking for a particular BRIDGenomics employee's phone or email?
The BRIDGenomics annual revenue was $200000 in 2024.
1 people are employed at BRIDGenomics.
BRIDGenomics is based in Friendsville, Tennessee.
The NAICS codes for BRIDGenomics are [54, 54171, 541, 541713, 5417].
The SIC codes for BRIDGenomics are [87, 873].